Vertex Pharmaceuticals VRTX
Healthcare · Biotechnology · Synthos Deep Dive · 2026-08-04
The Overview
Vertex makes medicines. For twenty years it worked on one disease — cystic fibrosis, an inherited condition that damages the lungs and was usually fatal in childhood — and it succeeded so completely that its drugs now generate over $10 billion a year and most people with the disease in wealthy countries take one. That single product family is 85% of the company.
That concentration is the risk, and Vertex has spent the last few years trying to fix it. In the three months to June, for the first time, you can see it working:
- CASGEVY, the world's first approved gene-editing treatment — a one-time procedure that functionally cures sickle-cell disease — brought in $76 million, up 151% on a year earlier, and has just been approved for children as young as two.
- JOURNAVX, the first genuinely new type of painkiller in decades and one that is not addictive, brought in $50 million, up more than 300%. About 240 million Americans now have insurance coverage for it.
- ALYFTREK, the newest cystic-fibrosis medicine, made $838 million in its first full year.
Total sales grew 12.5%. The company keeps 86 cents of every sales dollar as gross profit and spends 31 cents of every dollar on research — an unusually high figure that is the reason it keeps producing new medicines.
Here is what no stock screen currently shows. On 6 July Vertex agreed to buy another drug company, Crinetics, for $10 billion in cash. On 30 July it arranged a $4.5 billion loan to help pay for it, with $1 billion of that due back within a year. The deal is expected to complete before the end of September. A company that today has more cash than debt will shortly have considerably less of one and more of the other.
There is a specific reason to be careful about this. In 2024 Vertex bought another company and, under accounting rules, had to write the entire purchase price off as an expense immediately. The result: on $11 billion of sales, the company reported a $536 million loss and burned cash for the year. The quarterly report filed today says only that the Crinetics purchase "will be accounted for in the period that it closes." We do not know whether the same thing will happen again, and neither does anyone else outside the company.
The shares cost $478.71. That is about 22.5 times what analysts expect Vertex to earn in 2027 — and those forecasts do not yet include Crinetics' losses or the interest on the new loan. Our estimate of fair value is $510, about 6.5% above the price. The average analyst says $552.
- Downside Risk 6/10. Very profitable, but 85% of sales come from one product family, and a $10 billion cash purchase is landing now.
- Growth Quality 7/10. Accelerating, and for the first time diversifying in the actual numbers.
- Exponential Potential 7/10. A real discovery engine with three genuinely new medicines proving it can repeat. One of the two best in this batch.
Putting a number on it: our fair-value estimate is $510 against a current price of $541.69 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
"Rated 6 — an exceptionally profitable business with two concentrated exposures, one of which is about to be paid for in cash. Supports: gross margin of **86.0%**, operating margin of **37.4%** in the June quarter, interest coverage of **738x**, a current ratio of 3.19x, **beta of 0.305** — the second lowest in this batch — free cash flow of $3,193.8M in fiscal 2025, and $12,417.6M of cash and investments against $3,882.5M of total debt at 31 December 2025 (of which $1,953.2M is finance lease obligations). Against that: **TRIKAFTA/KAFTRIO alone was $10,312.7M of $12,074.6M of fiscal 2025 revenue — 85.4% of the company from one product family**, with the entire cystic-fibrosis franchise close to 93%; the pending **$10.0 billion Crinetics acquisition**, agreed 6 July 2026, funded with cash plus a **$4.5 billion delayed-draw term loan entered 30 July whose first $1.0 billion tranche matures 364 days after drawdown**, which converts a net-cash balance sheet into a levered one and appears in no screen; **fiscal 2024, when a single acquired in-process research and development charge turned $11.0 billion of revenue into a $535.6 million net LOSS and MINUS $492.6 million of operating cash flow** — the clearest possible demonstration of how violently one transaction can hit this income statement; research and development at **31.4% of revenue**, which is the price of the pipeline and is not discretionary; and a cluster of **four discretionary open-market sales by senior officers between 26 June and 2 July 2026** at prices from $482.50 to $524.99. A 6 rather than a 5 because concentration plus a large cash acquisition plus new term debt is three risks arriving together."
"Rated 7 — accelerating, diversifying, and finally showing it in the reported lines. Second-quarter revenue was **$3,333.9M, up 12.5%** on $2,964.7M, with the 10-Q reporting **net product revenue up 13% in the quarter and 11% in the half**, US revenue up 11% and ex-US up 14%. Fiscal 2025 revenue was $12,074.6M, up 9.6%, and revenue has risen in every one of the last six years, from $6,205.7M in fiscal 2020 — a 14.2% compound rate. **The diversification is the new part and it is real:** CASGEVY, the first approved CRISPR-based therapy, recorded **$76.4M in the June quarter, up 151% year on year and 78% sequentially**, and was approved by the FDA for children as young as two, which the 10-Q says makes approximately 5,500 additional patients eligible; JOURNAVX, the first new non-opioid analgesic class in decades, recorded **$49.6M, more than 300% growth**, with roughly 240 million lives now having reimbursed access; and ALYFTREK, the next-generation cystic-fibrosis triple, reached **$837.8M in its first full year** and is reimbursed in 25 countries. What holds this to a 7: consensus models FY2027 EPS growth of only **11.1%**, the base is still 85% one product family, and the last two reported quarters were narrow EPS MISSES ($5.03 against $5.11 and $4.73 against $4.74) after three consecutive beats."
"Rated 7 — one of the two genuine exponential candidates in this batch, and the reasons are mechanistic rather than narrative. Vertex did not find a drug; it built a **discovery platform for a protein-folding defect** and then produced four successive generations of CFTR modulator from it, each better than the last, culminating in ALYFTREK — and VX-828, a next-generation corrector, is in the clinic with proof-of-concept data expected in the second half of 2026. That is a repeatable engine, and it has now been pointed at three further disease areas with early commercial evidence in each: **CASGEVY is the first approved CRISPR gene-editing therapy anywhere** and is a one-time functional cure for sickle-cell disease and beta thalassemia, growing 151% year on year; **JOURNAVX (suzetrigine) is a peripherally acting NaV1.8 inhibitor — a new analgesic mechanism**, which an independent knowledge-base voice calls 'scientifically unequivocal' and a potential blockbuster, with Phase 3 diabetic peripheral neuropathy studies completing enrolment by end-2026; and a **nephrology franchise** with povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease. The constraints that keep this at 7 rather than higher: cystic fibrosis is a fixed and small patient population — growth there comes from geography, younger ages and survival, not from market expansion; CASGEVY is a complex one-time therapy whose absolute revenue remains under $80M a quarter after three years; and the pain franchise's commercial trajectory is, as the knowledge base itself notes, genuinely hard to model."
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
The Road Ahead
What we expect to matter in each window, and the evidence that would prove us wrong.
Short term 0-6 months
Neutral- Driver
- "A well-behaved stock about to absorb a $10 billion transaction whose accounting consequences are unknown. The technical picture is neutral to constructive: $478.71 is only **9.6% below the 52-week high of $529.59** and **30.6% above the low of $366.54**, sits **1.8% above a 50-day average of $470.01** and **5.5% above a 200-day of $453.58**, both rising; RSI is **51.1** and MACD **+0.42** — the most neutral technical readings in this batch. The three-month return is **+11.4%** against SPY's +7.6%. But the twelve-month return is **+3.6% against SPY's +24.3%**, a 20.7-point underperformance, so the recent strength follows a long period of going nowhere. The dominant short-term factor is not the chart: **the Crinetics acquisition is expected to close inside the third quarter, and the 10-Q says the accounting will be recognised in the period it closes.** Fiscal 2024 shows what that can look like — a single acquired in-process research charge produced a $535.6 million net loss on $11.0 billion of revenue. **Buying ahead of an accounting event of unknown magnitude, at a base fair value only 6.5% above spot, has no edge in it.**"
- What we’re watching
- "The Crinetics closing — shareholder vote, Hart-Scott-Rodino expiry, foreign clearances — and specifically **whether the purchase price is allocated substantially to acquired in-process research and development (expensed immediately, as in fiscal 2024) or to identifiable intangibles (amortised)**. The size of the drawdown under the $4.5 billion term loan and the terms on which the $1.0 billion 364-day tranche is refinanced. The 2026-11-02 print against consensus revenue of $3,397.8M and adjusted EPS of $4.88 — noting that the last two prints were narrow misses. CASGEVY and JOURNAVX quarterly revenues against $76.4M and $49.6M; both are compounding fast off small bases and both are the proof of the diversification thesis. And VX-828 proof-of-concept data, which management has guided to the second half of 2026."
- Confidence
- Medium
Medium term 6-24 months
Tailwind- Driver
- "The medium-term case is the arithmetic of diversification, and for the first time it is visible in reported revenue rather than in slides. In the June quarter, CASGEVY contributed **$76.4M growing 151% year on year** and JOURNAVX **$49.6M growing more than 300%** — together $126M, or 3.8% of quarterly revenue, from two products that did not exist commercially two years ago. Management guides (half weight) to **$500 million or more of non-cystic-fibrosis product revenue in 2026** and to full-year total revenue of **$12.95-13.10 billion**; consensus of $13,113M sits at the top of that range. The pipeline behind it is dense and dated: Phase 3 suzetrigine studies in diabetic peripheral neuropathy completing enrolment by end-2026; a povetacicept BLA in IgA nephropathy with an expected six-month FDA review via a priority review voucher; AMPLITUDE inaxaplin interim data in early 2027; a cystic-fibrosis filing for ages 2-5; and VX-828 proof of concept in the second half of 2026. **Crinetics adds a fifth area — endocrine disease — for $10.0 billion**, and the one independent knowledge-base voice on it thinks the price is defensible for a company of this size while warning that the floor value is probably nearer $1 billion per programme than the $5 billion the company implies."
- What we’re watching
- "Whether non-cystic-fibrosis revenue clears the $500 million management guides to, and whether it is still compounding at triple digits in 2027. Whether the chronic-pain indication — which one independent voice calls 'the higher-conviction driver' with a plausible $5-10 billion market at more than $10,000 a year — delivers positive Phase 3 data, because acute pain alone does not justify the pipeline value. Whether Crinetics closes on terms, what the purchase-price allocation does to reported earnings, and whether the liver-safety question the knowledge base raises about its lead asset materialises. Net leverage after the term-loan drawdown, from a starting point of net cash. And the competitive question the knowledge base raises indirectly: a 2025 claim identifies a newly public competitor in cystic fibrosis targeting Vertex's franchise, and 85% of revenue sits there."
- Confidence
- Medium
Long term 2+ years
Tailwind- Driver
- "The long-run case is that Vertex is one of very few companies that has demonstrated a **repeatable** ability to convert biological understanding into approved medicines, and it is now testing whether that skill generalises beyond one disease. The evidence for the skill is unusually hard: four successive generations of CFTR modulator, each superior, taking cystic-fibrosis revenue from nothing to **$10.3 billion a year** and turning a fatal childhood disease into a managed condition; the **first approved CRISPR gene-editing therapy in the world**; and the **first genuinely new analgesic mechanism to reach market in decades**. Research and development runs at **31.4% of revenue — $3,753.7 million in fiscal 2025** — which is what a real discovery engine costs and which almost no company at this margin level sustains. The financial model is exceptional: **86.0% gross margin**, 37-39% operating margin, essentially no capital intensity beyond manufacturing, and until July no meaningful debt. **What the next five years test is whether the CF playbook — deep mechanistic insight, serial improvement, pricing power in a small population — transfers to sickle cell, pain, kidney disease and now endocrinology.** The June quarter is the first in which all four legs produced revenue."
- What we’re watching
- "Cystic-fibrosis exclusivity and competition — 85.4% of revenue rests on TRIKAFTA/KAFTRIO, and the knowledge base flags at least one well-funded newly public competitor targeting the same pathway. Whether ALYFTREK successfully converts the installed base before that matters, and whether VX-828 extends the franchise again. Whether CASGEVY ever scales — it is a complex, expensive, one-time therapy and after three years it is running below $80 million a quarter. Whether the pain franchise reaches chronic indications, which is where the value is. Whether the Crinetics acquisition and the $4.5 billion term loan mark the beginning of a serial-acquirer phase, which would change the character of the company. Chief executive Reshma Kewalramani's capital-allocation record, of which Alpine Immune Sciences (a $535.6 million reported loss year) and Crinetics ($10.0 billion) are the two large data points."
- Confidence
- Medium
Exponential Potential
"Rated 7 — one of the two genuine exponential candidates in this batch, and the reasons are mechanistic rather than narrative. Vertex did not find a drug; it built a **discovery platform for a protein-folding defect** and then produced four successive generations of CFTR modulator from it, each better than the last, culminating in ALYFTREK — and VX-828, a next-generation corrector, is in the clinic with proof-of-concept data expected in the second half of 2026. That is a repeatable engine, and it has now been pointed at three further disease areas with early commercial evidence in each: **CASGEVY is the first approved CRISPR gene-editing therapy anywhere** and is a one-time functional cure for sickle-cell disease and beta thalassemia, growing 151% year on year; **JOURNAVX (suzetrigine) is a peripherally acting NaV1.8 inhibitor — a new analgesic mechanism**, which an independent knowledge-base voice calls 'scientifically unequivocal' and a potential blockbuster, with Phase 3 diabetic peripheral neuropathy studies completing enrolment by end-2026; and a **nephrology franchise** with povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease. The constraints that keep this at 7 rather than higher: cystic fibrosis is a fixed and small patient population — growth there comes from geography, younger ages and survival, not from market expansion; CASGEVY is a complex one-time therapy whose absolute revenue remains under $80M a quarter after three years; and the pain franchise's commercial trajectory is, as the knowledge base itself notes, genuinely hard to model."
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Clinical pipeline
Clinical-trial data for VRTX hasn’t been pulled yet — check back soon.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $552.43 (+15.4%) · median $576 · high $616 · low $350 (−26.9%) · 47 buy / 8 hold / 1 sell across 56 analysts |
| Valuation | 27.6x trailing GAAP diluted EPS · 25.2x trailing adjusted · 25.0x FY2026E · 22.5x FY2027E · 18.7x FY2028E · 9.16x EV/sales · 21.2x EV/EBITDA · P/B 6.00x |
| What the payload does not contain | Crinetics Pharmaceuticals acquisition agreed 2026-07-06: $85.00 per share in cash, approximately $10.0 BILLION of equity value, expected to close in Q3 2026. Plus a $4.5 billion senior unsecured delayed-draw term loan A entered 2026-07-30, first $1.0 billion tranche due 364 days after drawdown. Both are subsequent events in the 10-Q filed the day of this dive |
| The concentration | TRIKAFTA/KAFTRIO alone was $10,312.7M of $12,074.6M of FY2025 revenue — 85.4%. Adding ALYFTREK, the cystic-fibrosis franchise is close to 93% |
| The diversification, finally arriving | Q2 2026: CASGEVY $76.4M, +151% YoY and +78% sequentially — the first approved CRISPR therapy, now FDA-approved down to age two; JOURNAVX $49.6M, more than +300% YoY — the first new non-opioid analgesic class in decades, ~240M lives with reimbursed access |
| The warning in the history | Fiscal 2024: revenue $11,020.1M, operating income MINUS $232.9M, net income MINUS $535.6M, operating cash flow MINUS $492.6M — one acquired in-process research charge. The June 2024 quarter alone printed an operating loss of $3,514.7M |
| Conviction | 20 raw claims — but ELEVEN (55%) are the company's own VRTX_mgmt channel and are EXCLUDED from the pool. Nine independent claims remain across six channels. 4 homograph discards including "Vertex" meaning Google's AI platform |
| Technicals | −9.6% from the 52-week high of $529.59, +30.6% above the low of $366.54; +1.8% above the 50-DMA, +5.5% above the 200-DMA; RSI 51.1; MACD +0.42; beta 0.305; 12-month +3.6% vs SPY +24.3% |
What the experts actually said 14 traceable claims on VRTX · showing the highest-conviction voices
“CRISPR/Vertex's one-time therapy cures sickle cell and beta thalassemia and is already generating revenue; top holding in ARKG/ARKK.”
“CRISPR Therapeutics (top-10 in ARKK/ARKG) with Vertex has a one-treatment cure for sickle cell and beta thalassemia already generating revenue; convergence of sequencing plus CRISPR begins curing disease.”
“Vertex's ~$9-10B Crinetix buy (near-100% premium) is the kind of deal a $130B-cap company should do; floor value likely ~$1B+ per drug vs Vertex's $5B claim, main risk being adamelmant liver safety, but give Vertex the benefit of…”
“Reiterated FY2026 total revenue guidance of $12.95B–$13.1B, driven by continued CF growth plus $500M+ from non-CF products.”
“Guides continued investment across mid/late-stage programs plus ~$100M AIPR&D; only immaterial 2026 tariff cost impact expected.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $541.69, 8% above the 50-day average ($501), 17% above the 200-day average ($463) — an uptrend. 2% below the 52-week high of $553, 44% above the 52-week low of $377.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $541.69 is currently inside the band (band $470–$574).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 61.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 1.25, positive momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = VRTX · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What the business is, and the concentration
Vertex describes itself as a biotechnology company focused on serious diseases. Chief executive Reshma Kewalramani; approximately 6,400 employees per the vendor profile; Boston, Massachusetts; NASDAQ-listed since 1991. Beta 0.305 — the second lowest in this batch.
Revenue by product (seg_prod), and the concentration is the headline:
| Product | FY2025 | FY2024 | FY2023 | FY2022 | FY2025 share |
|---|---|---|---|---|---|
| TRIKAFTA / KAFTRIO | $10,312.7M | $10,238.6M | $8,944.7M | $7,686.8M | 85.4% |
| ALYFTREK (launched) | $837.8M | — | — | — | 6.9% |
| Manufactured Product, Other | $820.1M | $781.5M | — | — | 6.8% |
| KALYDECO (FY2023 and earlier) | — | — | $475.5M | $553.2M | — |
| ORKAMBI | — | — | $326.0M | $510.7M | — |
| SYMDEKO/SYMKEVI | — | — | $123.0M | $180.0M | — |
| Sum | $11,970.6M | $11,020.1M | $9,869.2M | $8,930.7M | |
| Reported revenue | $12,074.6M | $11,020.1M | $9,869.2M | $8,930.7M | |
| Unreconciled | $104.0M (0.9%) | $0 | $0 | $0 |
Two observations. First, seg_prod reconciles exactly in FY2022, FY2023 and FY2024 and is $104.0M short in FY2025 — 0.9%, which is collaborative and royalty revenue, small enough to accept but stated rather than hidden. Second, the vendor collapsed KALYDECO, ORKAMBI and SYMDEKO into "Manufactured Product, Other" from FY2024, which mirrors the company's own disclosure change as those older products declined.
The concentration is the defining fact about this company. TRIKAFTA and KAFTRIO — the same triple-combination therapy under two brand names — were 85.4% of fiscal 2025 revenue. Adding ALYFTREK, the cystic-fibrosis franchise is approximately 92.3%. Everything in the growth and exponential sections is about reducing that number, and it has barely moved: it was 90.6% in fiscal 2024.
seg_geo is REJECTED for FY2025 and the reason is arithmetic. FY2024 is clean: United States $6,684.9M + Europe $3,453.9M + Other Non-US $881.3M = $11,020.1M, matching reported revenue exactly. FY2025 reports United States $7,548.6M + Europe $3,460.3M + "Non-US" $5,445.1M. On no interpretation does that reconcile: if "Non-US" is inclusive of Europe, US plus Non-US is $12,993.7M against reported revenue of $12,074.6M — $919M too high; if exclusive, the three sum to $16,454.0M — $4,379M too high. The vendor renamed the residual line and appears to have populated it with something else. We do not use the FY2025 geographic block.
The 10-Q supplies the growth rates instead, and they are usable: "In the second quarter and first half of 2026, our U.S. total revenues increased 11% and 9% ... our ex-U.S. total revenues increased 14% and 12% ... primarily due to strong CF performance across multiple geographies, including ALYFTREK uptake, increased CASGEVY product revenues, and favorable impacts from foreign exchange." Ex-US is growing faster than US, which is consistent with ALYFTREK reimbursement expanding to 25 countries.
2. The corporate action the payload does not contain
On 6 July 2026 — twenty-nine days before this dive — Vertex agreed to acquire Crinetics Pharmaceuticals. The 8-K filed 2026-07-07 and the 10-Q filed 2026-08-04 both disclose it. The 10-Q's subsequent-events note is the clearest statement:
> "On July 6, 2026, we entered into an agreement and plan of merger to acquire (the 'Crinetics Acquisition') all of the issued and outstanding shares of common stock of Crinetics Pharmaceuticals, Inc., a publicly traded biotechnology company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors, for $85.00 per share in cash, for a total equity value of approximately $10.0 billion. The transaction is expected to close in the third quarter of 2026, subject to certain customary closing conditions. We will account for the acquisition in the period that it closes. We intend to fund the acquisition using a combination of our cash, cash equivalents, and proceeds from the 2026 Term Loan ... The Crinetics Acquisition is not conditioned on our receipt of financing."
And the financing, entered five days before this dive:
> "On July 30, 2026, we entered into a term loan credit agreement (the '2026 Term Loan') ... which provides for a $4.5 billion senior unsecured delayed draw term loan A facility. Amounts borrowed under the 2026 Term Loan will be used to finance a portion of the Crinetics Acquisition. Any amounts borrowed ... will become payable in full as follows: (a) a $1.0 billion tranche due 364 days after the amounts are borrowed ... (b) a $1.0 billion tranche due on [a later] date ..."
The 8-K adds the conditions: majority shareholder approval, Hart-Scott-Rodino expiry, foreign regulatory clearances, and no material adverse effect. A preliminary proxy was to be filed within ten business days of 6 July.
What the vendor payload contains about this: nothing. bal_a ends 31 December 2025, six months before the agreement. cf_a ends at the same date. No field in quote, profile, km_ttm, ratios_ttm or est reflects a $10.0 billion cash outflow or a $4.5 billion facility.
Why this matters more than the headline number — and the evidence is in Vertex's own recent history.
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow |
|---|---|---|---|---|
| FY2023 | $9,869.2M | $3,832.0M | $3,619.6M | +$3,537.3M |
| FY2024 | $11,020.1M | −$232.9M | −$535.6M | −$492.6M |
| FY2025 | $12,074.6M | $4,760.7M | $3,953.2M | +$3,631.4M |
In fiscal 2024 Vertex grew revenue 11.7% and reported a net LOSS of $535.6 million and NEGATIVE operating cash flow of $492.6 million. The cause is visible at quarterly resolution: the June 2024 quarter alone printed an operating loss of $3,514.7 million on revenue of $2,645.6 million, which is the acquired in-process research and development charge from the Alpine Immune Sciences acquisition expensed in full at close. A single transaction erased a year of earnings.
The 10-Q tells us nothing about how Crinetics will be treated beyond "in the period that it closes." If the purchase price is allocated substantially to acquired in-process research and development — the treatment when the acquired programmes have no alternative future use — the charge is expensed immediately and the third or fourth quarter of 2026 could look like the June 2024 quarter. If it is allocated to identifiable intangibles, it amortises. We do not know, and no forecast in the est block reflects either outcome.
The balance-sheet effect, using the last filing-verified figures. At 31 December 2025 Vertex held $5,087.8M of cash, $1,523.3M of short-term investments and $5,806.5M of long-term investments — $12,417.6M — against $3,882.5M of total debt, of which $1,953.2M is finance lease obligations. Net cash on the strictest measure (cash and short-term investments less all debt) was $2,728.6M; counting long-term investments, $8,535.1M. Spending $10.0 billion of that, plus drawing up to $4.5 billion of term debt, converts the strongest balance sheet in this batch into a levered one. VRTX's filings in this archive are prose-only, so the 30 June 2026 balance sheet is not recoverable and the exact starting position is not verifiable — see Section 5 — but the direction is unambiguous and the magnitude is disclosed.
One further note on the vendor's enterprise value. km_ttm.enterpriseValueTTM of $115,623,122,145 is market capitalisation less $5,875,000,000 of implied net cash. That figure reconciles to no combination we can construct from the 31 December 2025 balance sheet — cash less total debt gives $1,205.3M, cash plus short-term investments less total debt gives $2,728.6M, and adding long-term investments gives $8,535.1M. It is presumably drawn from a 30 June 2026 balance sheet we cannot see. We report it, flag it as unverifiable, and note that whatever the correct pre-deal figure, it is about to be reduced by $10.0 billion.
3. Growth, margins and the diversification arriving
Annual, from inc_a:
| Fiscal year | Revenue | YoY | Gross margin | Operating margin | Net income | Diluted EPS | R&D | R&D % |
|---|---|---|---|---|---|---|---|---|
| FY2020 | $6,205.7M | — | 88.1% | 46.0% | $2,711.7M | $10.44 | $1,829.5M | 29.5% |
| FY2021 | $7,574.4M | +22.1% | 88.1% | 36.7% | $2,342.1M | $9.09 | $3,051.1M | 40.3% |
| FY2022 | $8,930.7M | +17.9% | 87.9% | 48.2% | $3,322.0M | $12.97 | $2,655.8M | 29.7% |
| FY2023 | $9,869.2M | +10.5% | 87.2% | 38.8% | $3,619.6M | $14.05 | $3,162.9M | 32.0% |
| FY2024 | $11,020.1M | +11.7% | 86.1% | −2.1% | −$535.6M | −$2.08 | $3,630.3M | 32.9% |
| FY2025 | $12,074.6M | +9.6% | 85.0% | 39.4% | $3,953.2M | $15.46 | $3,753.7M | 31.1% |
Revenue has risen every single year, from $6.2 billion to $12.1 billion — a 14.2% compound rate over five years. Gross margin has drifted down 310 basis points over the period, which is the cost of gene therapy and pain products carrying different economics than small-molecule cystic-fibrosis drugs. Research and development at 29-40% of revenue every year is the defining cost, and the 40.3% in fiscal 2021 shows the company will spend when it has something to spend on.
Quarterly:
| Quarter | Revenue | YoY | Gross margin | Operating margin | Net income | Adj. EPS (earn_cal) | vs est. |
|---|---|---|---|---|---|---|---|
| Q2 2024 | $2,645.6M | — | 85.9% | −132.9% | −$3,593.6M | — | — |
| Q3 2024 | $2,771.9M | — | 85.8% | 40.3% | $1,045.4M | — | — |
| Q4 2024 | $2,912.0M | — | 85.5% | 35.2% | $913.0M | — | — |
| Q1 2025 | $2,770.2M | — | 86.9% | 22.7% | $646.3M | — | — |
| Q2 2025 | $2,964.7M | +12.1% | 86.3% | 38.8% | $1,032.9M | $4.52 | vs $4.29 |
| Q3 2025 | $3,076.4M | +11.0% | 86.5% | 38.6% | $1,082.9M | $4.80 | vs $4.57 |
| Q4 2025 | $3,227.1M | +10.8% | 85.6% | 40.3% | $1,191.1M | $5.03 | vs $5.11 — MISS |
| Q1 2026 | $2,986.9M | +7.8% | 86.8% | 38.1% | $1,031.4M | $4.47 | vs $4.24 |
| Q2 2026 | $3,333.9M | +12.5% | 85.3% | 37.4% | $1,099.8M | $4.73 | vs $4.74 — MISS |
Note the two operating-margin anomalies and what they are. The June 2024 quarter's minus 132.9% is the Alpine acquired in-process research charge. The March 2025 quarter's 22.7% is a further, smaller charge of the same character. Neither is an operating deterioration, and both are the pattern that makes the pending Crinetics accounting worth watching.
And note the beat series: +5.4%, +5.0%, −1.6%, +5.4%, −0.2%. Two of the last four prints were misses. They were narrow — eight cents and one cent — but for a company whose revenue is 85% a mature product and therefore highly forecastable, misses are more informative than they would be elsewhere. The earn_cal basis is consistent across all five rows, so the series is like-for-like.
The diversification, in the company's own numbers
From the 10-Q filed 2026-08-04:
> CASGEVY: "In the second quarter of 2026, we recorded $76.4 million of CASGEVY product revenues, representing a 78% increase compared to the first quarter of 2026 and a 151% increase compared to the second quarter of 2025. The U.S. Food and Drug Administration approved CASGEVY in children two years of age and older with SCD or TDT, making it the first genetic therapy indicated for children as young as two for both SCD and TDT. Approximately 5,500 patients with SCD or TDT may be eligible for treatment with CASGEVY for the first time with this approval."
> JOURNAVX: "In the second quarter of 2026, we recorded $49.6 million of JOURNAVX product revenues, representing a 71% increase compared to the first quarter of 2026 and a more than 300% increase compared to the second quarter of 2025."
> ALYFTREK: "In the second quarter of 2026, we secured reimbursement for ALYFTREK in four additional countries, including Spain, bringing the total number of countries where ALYFTREK is reimbursed to 25."
Together CASGEVY and JOURNAVX were $126.0 million in the June quarter — 3.8% of revenue. That is small, and it is the single most important small number in this dive: it is the first quarter in which two genuinely new franchises, in two entirely different therapeutic areas, both produced meaningful and rapidly compounding revenue. Management guides (half weight) to $500 million or more of non-cystic-fibrosis product revenue in 2026; the June quarter's run rate is consistent with that.
4. Balance sheet, cash flow and capital returns
A disclosure limitation first, because it governs this section. A direct count returns ZERO [TABLE] markers in Vertex's 10-K and both 10-Qs in this archive — the filings are prose-only. No balance sheet, income statement or cash-flow table is recoverable. Narrative numbers are recoverable and are used extensively — the Crinetics terms, the term-loan structure and tranching, product revenues, growth rates, cash-flow direction — but the 30 June 2026 balance sheet is not available from any source, and the vendor's most recent is 31 December 2025.
From bal_a at 31 December 2025 — vendor-sourced, not filing-verified:
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Cash and equivalents | $5,087.8M | $4,569.6M | $10,369.1M |
| Short-term investments | $1,523.3M | $1,546.3M | $849.2M |
| Long-term investments | $5,806.5M | $5,107.9M | $2,497.8M |
| Cash + all investments | $12,417.6M | $11,223.8M | $13,716.1M |
| Inventory | $1,686.8M | $1,205.4M | $738.8M |
| Goodwill + intangibles | $1,512.2M | $1,913.9M | $1,927.9M |
| Total assets | $26,142.8M | $22,533.2M | $22,730.2M |
| Short-term debt | $82.8M | $92.3M | $0 |
| Long-term debt | $1,846.5M | $0 | $0 |
| Finance lease obligations | $1,953.2M | $1,657.2M | $808.4M |
| Total debt | $3,882.5M | $1,749.5M | $808.4M |
| Total liabilities | $7,477.0M | $6,123.6M | $5,149.8M |
| Total equity | $18,665.8M | $16,409.6M | $17,580.4M |
A note on the debt composition that matters. Of $3,882.5M of totalDebt, $1,953.2M — half — is finance lease obligations, which for Vertex is principally its Boston headquarters and manufacturing facilities. The genuine borrowed debt at 31 December 2025 was $1,929.3M. debtToEquityRatioTTM of 0.098x and interestCoverageRatioTTM of 738x both reflect a company that has essentially never borrowed. That changes with the term loan.
Cash flow and capital returns:
| Fiscal year | Operating cash flow | Capex | Free cash flow | SBC | Buyback | Dividend |
|---|---|---|---|---|---|---|
| FY2022 | $4,129.9M | $204.7M | $3,925.2M | $491.3M | $172.0M | $0 |
| FY2023 | $3,537.3M | $258.4M | $3,278.9M | $581.2M | $427.6M | $0 |
| FY2024 | −$492.6M | $297.7M | −$790.3M | $698.5M | $1,177.1M | $0 |
| FY2025 | $3,631.4M | $437.6M | $3,193.8M | $685.9M | $2,017.4M | $0 |
| H1 2026 | $2,600M (10-Q: "increased to $2.6 billion") | — | — | — | — | $0 |
The 10-Q confirms the first-half figure directly: "Cash provided by operating activities increased to $2.6 billion in the first half of 2026, as compared to $1.9 billion in the first half of 2025." — a 37% increase.
Free cash flow of $3,193.8M in fiscal 2025 is a 26.5% margin and a 2.6% yield. Stock-based compensation of $685.9M is 5.5% of revenue — modest for biotech. The buyback stepped up to $2,017.4M in fiscal 2025, 1.7% of market capitalisation, and share count fell from 258.0M (FY2025 average) to 255.7M in the June quarter. No dividend, correctly reported as zero.
Whether the buyback survives a $10.0 billion acquisition and a $4.5 billion term loan is an open question the filings do not answer.
5. Valuation — priced in or room?
At $478.705 (market cap $121.50B, ~253.8M shares):
| Trailing (TTM) | FY2026E | FY2027E | FY2028E | FY2029E | |
|---|---|---|---|---|---|
| Revenue | $12,624.3M | $13,113.5M (12) | $14,410.4M (17) | $16,136.4M (18) | $17,831.1M (11) |
| Revenue growth | — | +8.6% (vs FY2025) | +9.9% | +12.0% | +10.5% |
| Adjusted EPS | $19.03 (four earn_cal actuals) | $19.135 (14) | $21.257 (14) | $25.579 (10) | $29.827 (4 — thin) |
| EPS growth | — | +0.6% | +11.1% | +20.3% | +16.6% |
| GAAP diluted EPS | $17.35 | — | — | — | — |
| P/E on adjusted EPS | 25.2x | 25.0x | 22.5x | 18.7x | 16.0x |
| P/E on trailing GAAP | 27.6x | — | — | — | — |
| EV/Sales (vendor EV, unverified) | 9.16x | — | — | — | — |
| EV/EBITDA (vendor EV) | 21.2x | — | — | — | — |
| Price/FCF | 32.0x | — | — | — | — |
| Price/book | 6.00x | — | — | — | — |
Estimate coverage is good through FY2028 and thins after: 12-18 analysts on the FY2026-FY2028 revenue lines, 14, 14 and 10 on the EPS lines, and only 4 on FY2029 and FY2030 EPS. The FY2029 and FY2030 rows are excluded from every conclusion. Note that the FY2028 EPS range — low $20.360, high $33.776, a 1.66:1 spread — is wide, and it is the pipeline disagreement expressed numerically.
Two estimate-block defects, both rejected.
est.ebitdaAvg and est.ebitAvg are fixed-ratio fabrications. ebitdaAvg is exactly 35.91% of revenueAvg in every year from FY2026 to FY2030; ebitAvg is exactly 34.16%. Vertex's actual fiscal 2025 EBITDA margin was 40.3%. Rejected in full.
est.netIncomeAvg EXCEEDS est.ebitAvg in EVERY forward year — arithmetically impossible. FY2026: $4,953.6M against $4,479.6M. FY2027: $5,454.4M against $4,922.6M. FY2028: $6,458.7M against $5,512.2M. FY2029: $7,695.4M against $6,091.1M. FY2030: $8,575.6M against $6,705.3M. A taxpaying company cannot earn more after interest and tax than before them, and here the defect is present in all five forward years rather than in one or two. netIncomeAvg is not used.
est.epsAvg is the only usable row and it validates. The FY2026 figure of $19.135 against first-half earn_cal actuals of $9.20 and a Q3 estimate of $4.88 implies a fourth quarter of $5.06, consistent with the $5.03 delivered in the December 2025 quarter. All forward valuation runs on epsAvg.
The critical caveat on those estimates. Crinetics was agreed on 6 July 2026 and the term loan on 30 July. Crinetics is a commercial-stage but loss-making endocrine company. Consensus EPS of $19.135 and $21.257 almost certainly reflects neither Crinetics' operating losses nor the interest cost on up to $4.5 billion of new borrowing, and certainly reflects no purchase accounting. A reader paying 22.5x FY2027E is paying it on an earnings stream computed for a company that will not exist in that form by the fourth quarter.
Peer context. The vendor peer set is a healthcare grab-bag — argenx, Bristol-Myers Squibb, CVS, GSK, HCA, McKesson, Regeneron, Sanofi, Stryker and Medtronic, which is also in this batch. Only argenx and Regeneron are comparable in character (high-margin, single-franchise-driven biotech). No peer multiples are supplied in the file, so no peer-multiple comparison is drawn.
5a. What today's price assumes (the inversion)
At $478.71 — 22.5x FY2027 consensus and 18.7x FY2028 — the price embeds:
- Adjusted EPS reaches $21.257 in 2027 and $25.579 in 2028 — +11.1% then +20.3% — (consensus; 14 and 10 analysts). The acceleration in 2028 is the pipeline: chronic pain, nephrology and continued CASGEVY scaling. It is not in the numbers yet.
- Cystic-fibrosis revenue does not decline. (Our number; TRIKAFTA/KAFTRIO was $10,312.7M, 85.4% of revenue.) This is the most fragile assumption in the price, and it is fragile because of concentration rather than because of any current evidence of erosion — the franchise grew and ALYFTREK is converting patients. A knowledge-base claim from August 2025 identifies a newly public competitor targeting cystic fibrosis with, in that claim's words, "low competition vs Vertex" as its own selling point.
- Non-cystic-fibrosis revenue clears $500 million in 2026 and keeps compounding. (Management guidance, half-weighted; corroborated by CASGEVY at $76.4M and JOURNAVX at $49.6M in the June quarter.) Together they annualise near $500M already.
- The $10.0 billion Crinetics acquisition does not produce a fiscal-2024-style earnings event. (Our number; the filing says only that it will be accounted for when it closes.) In fiscal 2024 one acquisition produced a $535.6 million net loss on $11.0 billion of revenue. The market appears to be assuming that does not repeat, and no disclosure supports or refutes that.
- The market keeps paying 19-25x forward earnings for a diversifying biotech. (Our number.) At 18x FY2028E the stock is $460; at 26x it is $665.
5b. The return bridge (why the multiple moves)
Expected return over the next twelve months decomposes as: EPS growth (+20.3%, from FY2027E $21.257 to FY2028E $25.579) + multiple drift (COMPRESSION, from 22.5x to roughly 19.5x on the respective forward year, −13%) + shareholder yield (+1.7%, entirely buyback, and at risk from the acquisition) ≈ +6% to +9%.
Our base assumes compression, and the reason is the acquisition rather than the business. Vertex is about to convert a net-cash balance sheet into a levered one, take on an unknown purchase-accounting charge, add a fifth therapeutic area with an asset an independent voice flags for liver-safety risk, and do it while 85% of revenue still comes from one product family. A modest de-rating during an integration is the normal treatment and is what we apply. If the deal closes cleanly with intangible rather than expensed accounting, and the pipeline delivers, the compression reverses — that is the bull case.
Almost all of the expected return is earnings growth. If the multiple simply held at 22.5x on FY2028E the price would be $576 (+20.3%); at 18x it would be $460 (−3.9%). The spread is 24 percentage points on a multiple assumption, against a base case of +6.5%.
5c. Variant perception (where we differ, what would surprise)
- Our largest divergence is on information, not opinion. Every screen shows Vertex as a debt-free, net-cash biotech. The filings show a company that four weeks ago committed $10.0 billion of cash and five days ago arranged $4.5 billion of term debt with a $1.0 billion 364-day tranche. Consensus estimates do not reflect either. A reader who has not opened the 10-Q filed on the day of this dive is valuing a different company.
- We differ from the market on how much weight the fiscal 2024 precedent deserves. The Alpine acquisition produced a $3,514.7 million single-quarter operating loss and turned the full year negative. Crinetics is roughly twice the size. We do not forecast the accounting treatment — we cannot — but we think a price that embeds no allowance for it is embedding an assumption, and the assumption is not disclosed.
- We think the diversification is being under-credited and the concentration correctly credited, and those partly offset. CASGEVY at +151% and JOURNAVX at +300% off small bases are the best forward evidence in this file, and the FDA's approval of CASGEVY down to age two adds approximately 5,500 eligible patients. But 3.8% of revenue growing fast does not yet change a company that is 85% one franchise, and the market is right not to pay for it until it does.
- On the knowledge base, our divergence is methodological and it is the most consequential in this batch. Eleven of the twenty claims naming Vertex come from the company's own management channel. A reader taking the lane at face value would see a densely covered, strongly bullish name. Under the house rule, management is excluded from the conviction pool, and what remains is nine independent claims across six channels — thin, mostly 2025-vintage, and net mildly positive. The apparent conviction is largely the company talking about itself.
- Positive surprise that would force a re-rate: Crinetics closing with the purchase price allocated to amortisable intangibles rather than expensed research; positive Phase 3 suzetrigine data in diabetic peripheral neuropathy, which opens chronic pain; VX-828 proof of concept in the second half of 2026; or non-cystic-fibrosis revenue clearing $200 million in a quarter.
- Negative surprise that would break the thesis: a fiscal-2024-style acquired-research charge on Crinetics; any evidence of cystic-fibrosis share loss or pricing pressure; a third consecutive quarterly EPS miss; the liver-safety issue the knowledge base raises about Crinetics' lead asset materialising; or the term loan being drawn in full and the 364-day tranche refinanced at a wide spread.
Synthos fair values
All three anchors are multiples of the FY2027 consensus adjusted-EPS distribution — mean $21.257, low $18.251, high $22.296 — which at 14 analysts is well covered. Cross-checked against FY2028E of $25.579 (10 analysts). None of these estimates reflects Crinetics, and that is disclosed rather than adjusted for, because we have no basis on which to adjust.
- Bear ~$330 — 18.1x the FY2027 consensus LOW of $18.251. Cross-check: 16.2x the FY2028 consensus low of $20.360; roughly 10% below the 52-week low of $366.54 and 6% below the street's low target of $350. The scenario: cystic-fibrosis revenue plateaus or a competitor takes share; the chronic-pain programmes disappoint; Crinetics produces a large expensed charge and its lead asset hits a safety issue; the term loan is drawn in full; and a concentrated, newly levered biotech earns a mid-teens multiple on flat earnings. −31.1%.
- Base ~$510 — 24.0x the FY2027 consensus MEAN of $21.257. Cross-check: 19.9x FY2028E; 26.7x FY2026E. Sensitivity, stated openly: 22x gives $468 — BELOW spot — and 26x gives $553, essentially the street. The whole answer lives in a 22-26x band and the low end of it is beneath the current price. The scenario: the cystic-fibrosis base holds, the four new franchises compound roughly on the consensus path, Crinetics closes and integrates without an extraordinary charge, and the multiple gives back a little during the integration. +6.5%, plus roughly 1.7% of buyback yield.
- Bull ~$620 — 27.8x the FY2027 consensus HIGH of $22.296. Cross-check: 18.4x the FY2028 consensus HIGH of $33.776; 17.1% above the 52-week high of $529.59 and 0.6% above the street's high target of $616. The scenario: suzetrigine succeeds in chronic pain and the analgesic franchise becomes the multi-billion opportunity one independent voice models; povetacicept establishes nephrology; CASGEVY scales on the paediatric approval; Crinetics proves accretive; and the market pays a platform multiple for a company that has now built four franchises from one discovery engine. +29.5%.
Base is 6.5% above spot; asymmetry roughly 0.95:1 — very slightly more downside than upside on our own numbers. That, plus an acquisition of unknown accounting consequence expected to close within weeks, is why this is a Watch.
6. Knowledge base — 20 claims, eleven of them the company's own voice
Raw entity hits: 20 — the second-largest lane in this batch. From the company's own VRTX_mgmt channel: 11 (55%). Independent claims in the conviction pool: 9, across 6 channels. Homograph discards: 4.
The management concentration, handled first, because it is the finding
Eleven of the twenty claims — 55% — come from VRTX_mgmt, all dated 2026-05-04, all restatements of guidance from the first-quarter results. Under the standing house rule, management voice is excluded from the conviction pool and quoted separately at half weight. This is a larger concentration than the ISRG case that produced the rule (there the lane was "half a management channel"; here it is 55%), and the required concentration sensitivity test is not a formality — it changes the reading of the lane from densely-covered-and-bullish to thinly-covered-and-mildly-positive.
The management claims, quoted at half weight and used only as disclosed guidance:
> 2026-05-04 · bullish · conviction 80 · horizon: fact
> "Reiterated FY2026 total revenue guidance of $12.95B–$13.1B, driven by continued CF growth plus $500M+ from non-CF products."
> 2026-05-04 · bullish · conviction 78 · horizon: thesis
> "Building fourth franchise in nephrology; expects expedited six-month FDA review of povetacicept IgAN BLA via Priority Review Voucher."
> 2026-05-04 · bullish · conviction 70
> "Expanding JOURNAVX access; ~240M individuals now have reimbursed access, adding ~10M Medicare Part D lives effective May 1."
> 2026-05-04 · bullish · conviction 62 · horizon: fact
> "On track to complete VX-828 (next-gen 3.0 CFTR corrector) dosing in H1 2026 and share proof-of-concept data in H2 2026."
> 2026-05-04 · neutral · conviction 50 · horizon: fact
> "Resumed zimislecel T1D dosing after manufacturing analysis; expects to provide updated study-completion timelines later in 2026."
That last one is worth isolating: it is the only management claim in the set that discloses a problem — a type 1 diabetes cell-therapy programme that was paused for a manufacturing issue and has resumed with timelines not yet restated. It is tagged neutral at conviction 50, the lowest of the eleven, which is the company grading its own bad news. This is exactly why management claims are excluded from conviction pools.
The nine independent claims — the actual lane
The most recent, and the only independent voice on the acquisition:
> 2026-07-10 · bullish · conviction 55 · horizon: thesis · entities: VRTX, CRNX · speaker: Paul Matis · channel: biotech_hangout · speaker_role: independent
> "Vertex's ~$9-10B Crinetix buy (near-100% premium) is the kind of deal a $130B-cap company should do; floor value likely ~$1B+ per drug vs Vertex's $5B claim, main risk being adamelmant liver safety, but give Vertex the benefit of the doubt."
This claim is the single most useful item in the lane and it deserves attention for three reasons. First, it independently corroborates a transaction the vendor payload knows nothing about — a claim dated four days after the merger agreement, naming the size and the premium correctly. Second, it is genuinely two-sided: it endorses the strategic logic while stating that the acquired programmes are probably worth about a fifth of what the acquirer implies. Third, it names a specific falsifiable risk — liver safety on the lead asset — which is exactly the kind of watchable item this process exists to surface. (The claim contains an apparent transcription of the target's name and a drug name; both are reproduced as stored.)
The JOURNAVX cluster — four claims from one episode on 2025-08-28, and the best independent analysis in the lane:
> bullish · conviction 70: "Journavx (NAV 1.8) is a landmark non-addictive analgesic acting peripherally; scientifically unequivocal, could become a blockbuster."
> neutral · conviction 55: "Acute-pain launch is hard to model and adoption curves for non-life-saving acute drugs are slow; beating consensus this year would be the real stock win."
> bullish · conviction 60: "Chronic-pain opportunity is the higher-conviction driver — >$10k/yr pricing and failed alternatives make a multi-billion (5-10B) market easy to model."
> bullish · conviction 60: "Large-cap quality names retrace pipeline failures fast on scarcity value and defensive investing, not fundamental enthusiasm."
Read together, these four are more useful than any single bullish claim: the science is sound, the acute launch will be slow, the value is in chronic pain, and the stock will be supported for reasons unrelated to fundamentals. The June-quarter datum — JOURNAVX at $49.6M, growing 71% sequentially — is consistent with a slow-but-real acute launch, exactly as the neutral claim predicted.
On CASGEVY:
> 2025-06-05 · bullish · conviction 70 · speaker: Cathie Wood · channel: invest_like_the_best · speaker_role: independent
> "CRISPR Therapeutics (top-10 in ARKK/ARKG) with Vertex has a one-treatment cure for sickle cell and beta thalassemia already generating revenue; convergence of sequencing plus CRISPR begins curing disease."
> 2025-06-05 · bullish · conviction 85 · channel: we_study_billionaires · no named speaker · entities: CRISPR Therapeutics, CRSP, Vertex, VRTX
> "CRISPR/Vertex's one-time therapy cures sickle cell and beta thalassemia and is already generating revenue; top holding in ARKG/ARKK."
These two are the same observation from two channels on the same date and are counted as two claims with the duplication noted.
Two further claims, both indirectly negative and included for that reason. A 2025-08-27 biotech_hangout claim describes a recent initial public offering, Sionna, as a cystic-fibrosis company with "low competition vs Vertex" — a competitor explicitly aiming at 85% of Vertex's revenue. And a 2025-10-01 empire claim uses Vertex as an example that "great products ... still struggled" in an unrelated context, which is a neutral aside rather than a view.
Homograph discipline — four discards
| Collision | Count | Examples |
|---|---|---|
| "Vertex" meaning Google's Vertex AI platform | 2 | "75% of GCP customers active on Vertex" (all_in, Freeberg); "Vertex AI usage is up 40X on a token basis" (management voice of another company) |
| "Vertex" as a generic benchmark for aspiring biotechs | 2 | "where the next Alnylam or Vertex comes from"; "more independents aiming to be the next Vertex" |
Both classes are exactly the kind of noise that inflates a lane if not checked, and the AI-platform collision is a new entry for the catalogue.
Conclusion on the lane
Before the management exclusion, this looks like a densely covered, strongly bullish name: 20 claims, overwhelmingly positive. After it, the honest description is nine independent claims from six channels, most from 2025, net mildly positive, with the single most recent and most specific claim being a balanced assessment of the Crinetics acquisition that endorses the strategy while questioning the price. Conviction Low, breadth 6, net positive-low-after-management-exclusion. The management exclusion is the single largest adjustment made to any knowledge-base lane in this batch and it is stated in full rather than performed silently.
7. Data integrity — what we rejected and why
Nine findings.
1. THE MAJOR FINDING — a $10.0 billion acquisition and a $4.5 billion term loan appear in NO vendor field. The 10-Q filed 2026-08-04 and the 8-K filed 2026-07-07 disclose the Crinetics Pharmaceuticals merger agreement of 6 July 2026 at $85.00 per share in cash for approximately $10.0 billion of equity value, expected to close in Q3 2026, and the 2026 Term Loan entered 30 July 2026 — a $4.5 billion senior unsecured delayed-draw term loan A facility with a $1.0 billion tranche due 364 days after drawdown. bal_a and cf_a both end 31 December 2025. est contains no adjustment. We present both from the filings and note that consensus EPS reflects neither.
2. Vertex's filings are PROSE-ONLY — stated, not worked around. A direct count returns zero [TABLE] markers in the 10-K filed 2026-02-13 and both 10-Qs. No balance sheet, income statement or cash-flow table is recoverable. Narrative numbers were extracted extensively — the Crinetics terms and structure, the term-loan tranching, CASGEVY and JOURNAVX quarterly revenues and growth, ALYFTREK reimbursement country count, US and ex-US growth rates, product-revenue growth, and first-half operating cash flow — but the 30 June 2026 balance sheet does not exist in this archive and the vendor's most recent is six months older than the deal.
3. seg_geo for FY2025 does not reconcile on any interpretation — REJECTED. FY2024 is clean (US $6,684.9M + Europe $3,453.9M + Other Non-US $881.3M = $11,020.1M exactly). FY2025 reports US $7,548.6M + Europe $3,460.3M + "Non-US" $5,445.1M; inclusive of Europe the US-plus-Non-US total is $12,993.7M against reported revenue of $12,074.6M ($919M too high), and exclusive the three sum to $16,454.0M ($4,379M too high). The vendor renamed the residual line between years and the value is not interpretable. The 10-Q's stated growth rates are used instead.
4. est.netIncomeAvg EXCEEDS est.ebitAvg in ALL FIVE forward years — REJECTED. FY2026 $4,953.6M against $4,479.6M; FY2027 $5,454.4M against $4,922.6M; FY2028 $6,458.7M against $5,512.2M; FY2029 $7,695.4M against $6,091.1M; FY2030 $8,575.6M against $6,705.3M. This is the data-contract defect in its most complete form — every forward year, not one or two.
5. est.ebitdaAvg and est.ebitAvg are fixed-ratio fabrications — REJECTED. ebitdaAvg is exactly 35.91% of revenueAvg and ebitAvg exactly 34.16% in every year FY2026 to FY2030, against an actual fiscal 2025 EBITDA margin of 40.3%.
6. km_ttm.enterpriseValueTTM implies net cash of $5,875M that reconciles to nothing verifiable — used with the caveat stated. The vendor's $115,623,122,145 is market capitalisation less exactly $5,875,000,000. Against the 31 December 2025 balance sheet, cash less total debt gives $1,205.3M, cash plus short-term investments less total debt gives $2,728.6M, and adding long-term investments gives $8,535.1M. None matches. It is presumably a 30 June 2026 figure we cannot see because the filings are prose-only. Reported, flagged, and noted as about to be reduced by $10.0 billion in any case.
7. seg_prod is $104.0M short of reported revenue in FY2025 — accepted with the gap stated. The three product lines sum to $11,970.6M against $12,074.6M, a 0.9% shortfall which is collaborative and royalty revenue. FY2022, FY2023 and FY2024 reconcile exactly. Not a material defect, but recorded because the LOW and SPGI files in this batch showed how informative such gaps can be.
8. earn_cal.revenueActual for 2026-02-12 is $3,190.0M against inc_q's $3,227.1M for the December 2025 quarter — a $37.1M (1.2%) discrepancy. Small and unexplained. All other earn_cal revenue figures match inc_q exactly, including the June 2026 quarter at $3,333.9M. We use inc_q and note the one-row difference.
9. returnOnEquityTTM is null in ratios_ttm against 23.31% in km_ttm — the same two-block disagreement seen on LOW, NOW and SPGI in this batch. We use the km_ttm figure with the caveat that equity is about to be reduced by a $10.0 billion cash outflow. returnOnInvestedCapitalTTM of 17.3% is quoted alongside.
Not defects, correctly reported and independently confirmed: inc_q June-quarter revenue of $3,333.9M matches the earnings-calendar actual exactly; the fiscal 2024 loss and the June-2024 operating loss of $3,514.7M are correctly reported and are real, not artefacts; dividendPerShareTTM of zero is correct — Vertex pays no dividend; interestCoverageRatioTTM of 738x is consistent with $1,929.3M of borrowed debt at pre-2026 rates; stockBasedCompensationToRevenueTTM of 5.46% reconciles to $685.9M on $12,074.6M; researchAndDevelopementToRevenueTTM of 31.4% reconciles to $3,753.7M; profile.currency and inc_a[0].reportedCurrency are both USD — no currency mixing; and earn_cal uses a consistent adjusted basis across all five reported rows, so the beat-and-miss series is like-for-like.
8-K scan — this is where the acquisition was found. The three retained 8-Ks are 2026-05-13 (Items 5.02 and 5.07 — director and officer matters, annual meeting results), 2026-07-07 (Item 1.01 — the Crinetics merger agreement, quoted in Section 2; the single most consequential document in this dive) and 2026-08-03 (Item 2.02 — second-quarter results, cover document only, Exhibit 99.1 not extracted). The term-loan agreement of 30 July 2026 does not appear in the 8-K archive and was found in the 10-Q's subsequent-events note.
Non-equity tripwire — checked and passed. VRTX is common stock, NASDAQ-listed. The $478.71 price is not par-like; beta is 0.305, which is unusually low and warranted the check — but there is no dividend at all, which rules out a fixed-income-like instrument; volume was 1.93M shares (~$923M of turnover); and the 52-week band of $366.54 to $529.59 is a 44% range. This is common equity, and the low beta is a genuine property of a biotech whose revenue is a reimbursed chronic therapy rather than an instrument artefact.
8. Technicals
- Price $478.705, up 1.70% on the day. −9.6% from the 52-week high of $529.59; +30.6% above the low of $366.54. Position within the annual range: 68.7th percentile.
- Moving averages, both below and both supportive: +1.8% above a 50-day of $470.01; +5.5% above a 200-day of $453.58. The 50-day is above the 200-day.
- RSI 51.1 and MACD +0.42 — the most neutral technical readings in this batch. There is no momentum signal here in either direction.
- Maximum drawdown from the six-year peak: −9.6%, identical to the distance from the 52-week high.
- Relative performance: 3-month +11.4% vs SPY +7.6% and QQQ +7.7% — outperformance; 6-month +1.4% vs SPY +11.1%; 12-month +3.6% vs SPY +24.3% and QQQ +30.8% — a 20.7-point underperformance.
- Beta 0.305 — the second lowest in this batch after Progressive's 0.246.
- Sentiment: 47 buy, 8 hold, 1 sell across 56 analysts. Consensus $552.43 (+15.4%), median $576 (+20.3%), high $616 (+28.7%), low $350 (−26.9%) — the low target is 36% below the median, which is a wide dispersion and reflects the concentration risk.
What the technical picture does to the entry. Nothing here argues for urgency in either direction — RSI at 51 and MACD at 0.42 are the definition of no signal. The stock has quietly gone nowhere for a year while the market rose 24%, then rallied 11% in three months. With a base fair value 6.5% above spot and an acquisition of unknown accounting consequence expected to close within weeks, the technical neutrality is convenient: there is no cost to waiting.
9. Insiders — a genuine cluster of discretionary selling
| Date | Person | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-21 | Ourania Tatsis | EVP, Chief Regulatory & Quality Officer | A-Award | 8,251 | $0 |
| 2026-07-21 | Amit Sachdev | EVP, Chief Patient & External Affairs Officer | A-Award | 8,251 | $0 |
| 2026-07-15 | Bruce I. Sachs | Director | A-Award | 99.941 | $0 |
| 2026-07-15 | Alan M. Garber | Director | A-Award | 31.56 | $0 |
| 2026-07-02 | Ourania Tatsis | EVP, Chief Regulatory & Quality Officer | S-Sale | 1,500 | $524.99 |
| 2026-07-02 | Duncan McKechnie | EVP, Chief Commercial Officer | S-Sale | 1,541 | $519.00 |
| 2026-07-01 | Joy Liu | EVP and Chief Legal Officer | S-Sale | 828 | $502.71 |
| 2026-06-26 | Carmen Bozic | EVP and Chief Medical Officer | S-Sale | 596 | $482.50 |
Four discretionary open-market SALES by four different executive vice presidents in a seven-day window, at prices from $482.50 to $524.99. These are S-Sale transactions, not tax withholding — they are decisions to sell.
The honest reading, carefully. The sizes are small — 596 to 1,541 shares, roughly $288,000 to $788,000 each, $1.85 million in total — and executives at this level routinely sell under pre-arranged plans for diversification and liquidity. The file does not indicate whether these were Rule 10b5-1 plan sales. What makes the cluster notable rather than routine is the timing and the composition: four C-suite officers including the Chief Commercial Officer and the Chief Medical Officer, in the week bracketing 1 July, at prices 5-10% above the current price — and the Crinetics merger agreement was signed on 6 July. We record this as a mild negative and explicitly decline to draw any stronger inference, because the sizes are small and the plan status is unknown.
The remaining four transactions are routine equity grants at a zero price. The file contains zero open-market purchases.
10. Verdict, kill-criteria and flip conditions
Watch.
What is genuinely excellent: an 86.0% gross margin and a 37-39% operating margin on a $12.6 billion revenue base; revenue that has risen every year for six years, compounding 14.2%; research and development at 31.4% of revenue funding a discovery engine that has produced four generations of CFTR modulator, the world's first approved CRISPR therapy, and the first new non-opioid analgesic mechanism in decades; a June quarter in which CASGEVY grew 151% and JOURNAVX grew more than 300%, the first period in which the diversification is visible in reported revenue rather than in guidance; $12.4 billion of cash and investments against $1.9 billion of borrowed debt at the last verified date; 738x interest coverage; beta of 0.305; free cash flow of $3.19 billion; and a street at 47 buy, 8 hold, 1 sell.
What holds us back: 85.4% of fiscal 2025 revenue from TRIKAFTA and KAFTRIO alone, and roughly 92% from cystic fibrosis, into which the knowledge base identifies a newly funded competitor; a $10.0 billion all-cash acquisition agreed twenty-nine days ago and a $4.5 billion term loan entered five days ago, neither of which appears in any vendor field and neither of which is in consensus estimates; a fiscal 2024 in which a single acquisition of half that size produced a $535.6 million net loss and minus $492.6 million of operating cash flow, with the 10-Q saying only that Crinetics "will be accounted for in the period that it closes"; two of the last four earnings prints being misses; a knowledge-base lane that is 55% the company's own management voice, reducing to nine independent claims after the required exclusion; four discretionary C-suite sales in the week around 1 July; and a base fair value of $510, only 6.5% above spot, whose lower sensitivity bound of 22x sits below the current price.
The distinction that matters. This is a very good company and the objection is one of timing and information, not of quality. Vertex is about to do the largest transaction in its history, funded partly with the first meaningful debt it has ever carried, with an accounting treatment that its own recent history shows can erase a year of reported earnings — and the entire estimate stack on which the 22.5x forward multiple rests was computed before any of it happened. The deal is expected to close inside the third quarter, which is to say within weeks. Waiting costs 6.5% of base-case upside and buys the single largest missing piece of information in this file.
Pre-registered KILL criteria — what would take this to Avoid:
- A fiscal-2024-style acquired in-process research and development charge on the Crinetics close large enough to produce a reported loss year, combined with any sign of pipeline disappointment.
- Any evidence of cystic-fibrosis revenue decline or share loss, given 85.4% concentration — this is the only exposure large enough to be existential.
- Negative Phase 3 suzetrigine data in diabetic peripheral neuropathy, which would remove the chronic-pain opportunity that the knowledge base's own analysis calls "the higher-conviction driver".
- The liver-safety issue the knowledge base raises about Crinetics' lead asset materialising after a $10.0 billion purchase.
- A third consecutive quarterly EPS miss, from a company whose revenue base should be among the most forecastable in healthcare.
- The $4.5 billion term loan being drawn in full with the 364-day tranche refinanced at a wide spread, which would signal the acquisition strained the balance sheet more than expected.
Pre-registered FLIP conditions — what would take this to Buy — Tactical:
- The Crinetics acquisition closing with the purchase price allocated substantially to amortisable intangibles rather than expensed research, at a price still below roughly $500. This is the single most likely path to a Buy and it is expected within weeks.
- Price below approximately $420 (19.8x FY2027E, 16.4x FY2028E) with no fundamental deterioration. At $420 the base case is +21% against a bear case only 21% lower.
- Non-cystic-fibrosis revenue clearing $200 million in a single quarter, against $126.0 million in the June quarter — the clearest possible evidence the concentration is genuinely breaking down.
- Positive VX-828 proof-of-concept data in the second half of 2026, which would extend the cystic-fibrosis franchise a fifth generation and directly address the 85% concentration risk.
- Positive Phase 3 suzetrigine data in chronic pain, which the knowledge base independently models as a $5-10 billion opportunity.
Where VRTX fits in the Synthos Framework Portfolio. The biotechnology sleeve — the platform's anchor thesis — at 0% today with a 2-2.5% target on a clean Crinetics close or a fill near $420. Batch overlap note: Medtronic (MDT) is in this batch and appears in Vertex's vendor peer set, but they share only a healthcare sector code and no driver; MDT is a device manufacturer and VRTX a discovery-led biotech. Within Synthos's own diseases-of-aging thesis, Vertex is the highest-quality expression of "mechanistic biology converted into approved medicine" available at this market capitalisation, and that is why the verdict is Watch-with-a-named-trigger rather than a dismissal. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $478.71.
Single biggest risk: 85.4% of revenue from one product family, at the exact moment the company is spending $10.0 billion of cash and borrowing $4.5 billion on a fifth therapeutic area. TRIKAFTA and KAFTRIO were $10,312.7 million of $12,074.6 million of fiscal 2025 revenue. Cystic fibrosis is a small, well-served, genetically defined population; growth comes from geography, younger age groups and survival, all of which are finite. Nothing in the current numbers shows erosion — the franchise grew and ALYFTREK is converting the base — but a single competitive, safety or reimbursement event in that one franchise would take out five-sixths of the revenue, and there is no second leg large enough to absorb it: CASGEVY and JOURNAVX together were 3.8% of the June quarter. The company knows this, which is precisely why it is buying Crinetics — and the acquisition is therefore both the mitigation and, in the near term, an additional risk, because $10.0 billion of cash and $4.5 billion of new debt are being committed to solve a problem that has not yet arrived.
Provenance & disclosures
- Traceability: 20 raw knowledge-base entity claims name Vertex — the second-largest lane in this batch — but ELEVEN of them (55%) come from the
VRTX_mgmtchannel: the company's own management, all dated 2026-05-04, all restatements of first-quarter guidance. Under the standing house rule these are EXCLUDED from the conviction pool and quoted at half weight, and the required concentration sensitivity test materially changes the reading: removing them leaves nine independent claims across six channels (biotech_hangout 5, we_study_billionaires 1, invest_like_the_best 1, empire 1, eli_lilly_ceo 1), net mildly positive and mostly 2025-vintage, rather than a densely covered strongly bullish lane. This is the single largest knowledge-base adjustment made in this batch and it is stated in full rather than performed silently. The most consequential independent claim is Paul Matis (biotech_hangout, 2026-07-10, named speaker,speaker_role: independent, conviction 55), which independently corroborates the Crinetics acquisition four days after signing, endorses the strategic logic for a company of this size, and simultaneously argues the assets are worth roughly a fifth of the implied value while naming a specific liver-safety risk. A four-claim biotech_hangout cluster from 2025-08-28 provides the best independent analysis of JOURNAVX, including the caution that acute-pain adoption curves are slow and that chronic pain is the higher-conviction driver at a $5-10 billion market. Cathie Wood (invest_like_the_best, 2025-06-05, named independent, conviction 70) and an unattributed we_study_billionaires claim of the same date cover CASGEVY. Two further claims are indirectly negative and are included for that reason: one identifies a newly public cystic-fibrosis competitor positioning on "low competition vs Vertex". Homograph discards, 4 total: "Vertex" meaning Google's Vertex AI platform (2 claims, one of which is management voice of a different company), and "Vertex" used as a generic aspirational benchmark for other biotechs (2 claims). All quotes are verbatim from the stored claim text. - Data as-of: most recent filing-verified financials 2026-06-30, from the 10-Q filed 2026-08-04 — the day this dive was struck (product revenues by brand, US and ex-US growth rates, the Crinetics merger terms, the 2026 Term Loan structure and tranching, first-half operating cash flow, and the pipeline update) · annual statements fiscal 2025 ended 2025-12-31 from
inc_a/bal_a/cf_a· estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873601 = 2026-08-04T20:00:01Z ($478.705, +1.70%; 50-DMA $470.01; 200-DMA $453.58; RSI 51.1; MACD +0.42; beta 0.305) · knowledge-base claims 2026-08-04. Fiscal note: Vertex's fiscal year is the calendar year. All figures come from the Synthos vendor data file for VRTX or from the SEC filings in the VRTX archive; no figure comes from memory, recall or external retrieval. - Filing archive contents and its central limitation: 10-K filed 2026-02-13 (fiscal 2025); 10-Q filed 2026-05-05 (March 2026 quarter); 10-Q filed 2026-08-04 (June 2026 quarter); 8-K filed 2026-05-13 (Items 5.02 and 5.07 — officer and annual-meeting matters); 8-K filed 2026-07-07 (Item 1.01 — the Crinetics merger agreement at $85.00 per share in cash, with the full condition set; the single most consequential document in this dive); 8-K filed 2026-08-03 (Item 2.02, second-quarter results — cover document only). CRITICAL: a direct count returns ZERO
[TABLE]markers across the 10-K and both 10-Qs. Vertex's filings in this archive are prose-only, and no statement table is recoverable. Narrative numbers were extracted and used extensively, but the 30 June 2026 balance sheet does not exist in any available source, and the vendor's most recent balance sheet (31 December 2025) predates both the acquisition agreement and the term loan. The 2026 Term Loan agreement of 30 July 2026 does not appear in the 8-K archive and was found only in the 10-Q's subsequent-events note. - Where the filings contradicted or corrected the vendor (detailed in Section 7): the $10.0 billion Crinetics acquisition (agreed 2026-07-06, $85.00 per share cash, expected to close Q3 2026) and the $4.5 billion delayed-draw term loan A (entered 2026-07-30, first $1.0 billion tranche due 364 days after drawdown) appear in NO vendor field, and consensus EPS estimates reflect neither Crinetics' losses nor the interest cost;
seg_geofor FY2025 rejected outright because it reconciles on no interpretation (US plus "Non-US" overshoots reported revenue by $919M; the three lines together overshoot by $4,379M), with the 10-Q's stated US +11% and ex-US +14% growth rates used instead;est.netIncomeAvgrejected for exceedingest.ebitAvgin ALL FIVE forward years;est.ebitdaAvgandest.ebitAvgrejected as fixed-ratio fabrications at exactly 35.91% and 34.16% of revenue in every year against an actual fiscal 2025 EBITDA margin of 40.3%;km_ttm.enterpriseValueTTM's implied net cash of $5,875M flagged as reconciling to no combination available from the 31 December 2025 balance sheet and unverifiable because the filings are prose-only;seg_prodnoted as $104.0M (0.9%) short of reported revenue in FY2025 while reconciling exactly in the three prior years;earn_cal.revenueActualfor 2026-02-12 noted as $37.1M belowinc_qfor the same quarter, the only such discrepancy in the series;returnOnEquityTTMnoted as null inratios_ttmagainst 23.31% inkm_ttm. Where vendor and filing AGREED — worth recording:inc_qJune-quarter revenue of $3,333.9M matches the earnings-calendar actual exactly; the fiscal 2024 reported loss and the June-2024 operating loss of $3,514.7M are correctly reported and are genuine;dividendPerShareTTMof zero is correct;researchAndDevelopementToRevenueTTMof 31.4% andstockBasedCompensationToRevenueTTMof 5.46% both reconcile to the income statement. - Basis note: analyst estimates and
earn_calactuals are adjusted (non-GAAP); reported diluted EPS is GAAP. Trailing adjusted EPS is $19.03 against trailing GAAP diluted of $17.35, a 9.7% gap driven principally by stock-based compensation ($685.9M, 5.5% of revenue) and acquired-intangible amortisation. Theearn_calbasis is consistent across all five reported rows, so the beat-and-miss series (+5.4%, +5.0%, −1.6%, +5.4%, −0.2%) is like-for-like — and it shows two misses in the last four prints, which for a company with a highly forecastable revenue base is more informative than it would be elsewhere. Forward multiples use consensus adjusted EPS; the trailing multiple is shown on both bases (25.2x adjusted, 27.6x GAAP diluted). The GAAP series contains two acquisition-driven distortions — the June 2024 quarter at minus 132.9% operating margin and the March 2025 quarter at 22.7% — and both are identified rather than smoothed. - Estimate coverage: 12-18 analysts on the FY2026 to FY2028 revenue lines and 14, 14 and 10 on the corresponding EPS lines — adequate; only 4 analysts on FY2029 and FY2030 EPS, both of which are excluded from every conclusion. The fair-value anchors rest on the FY2027 row (14 analysts). The FY2028 EPS distribution — low $20.360, mean $25.579, high $33.776, a 1.66:1 spread — is the honest measure of pipeline disagreement and is quoted rather than averaged away. A further coverage caveat governs everything: no estimate in the block postdates the 6 July Crinetics agreement in any way we can verify, and none can reflect the 30 July term loan.
- Peer note: the vendor peer set (argenx, Bristol-Myers Squibb, CVS, GSK, HCA, McKesson, Medtronic, Regeneron, Sanofi, Stryker) is a healthcare grab-bag matched on sector; only argenx and Regeneron resemble Vertex in character. Medtronic is also in this batch and shares no driver with Vertex. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn.
- Fair-value caveat: the $330 / $510 / $620 anchors are multiples of the FY2027 consensus adjusted-EPS distribution — 18.1x the low of $18.251, 24.0x the mean of $21.257, and 27.8x the high of $22.296 — cross-checked against the FY2028 distribution. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 22x gives $468, which is BELOW the current price, and 26x gives $553, which is essentially the street. The most important caveat is that all three anchors rest on estimates struck before the $10.0 billion Crinetics acquisition and the $4.5 billion term loan, and we do not adjust them because we have no disclosed basis on which to do so — the 10-Q says only that the acquisition "will be accounted for in the period that it closes."
- Timing: second-quarter results were released 2026-08-03, one day before this dive, and the 10-Q filed 2026-08-04, the day of it — this is the freshest filing in the batch. The next scheduled print is 2026-11-02, 90 days away. But the dominant near-term event is unscheduled: the Crinetics acquisition is expected to close inside the third quarter of 2026, which is to say within weeks, and the verdict is set with that as an explicit input. 2026-08-04 was a firm day for the stock (+1.70%); the 10-Q filing is the only company-specific event for that date in this file.
- Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
- Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
- Version: 2026-08-04-full.